Published Date: 16-Jul-2020
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report LAMEA Liver Disease Diagnostics Market, published by KBV research, the LAMEA Liver Disease Diagnostics Market would witness market growth of 7.6% CAGR during the forecast period (2020-2026).
The Brazil market dominated the LAMEA Laboratory tests Market by Country in 2019, thereby, achieving a market value of $129.2 Million by 2026. The Argentina market would witness a CAGR of 8.6% during (2020 - 2026). Additionally, The UAE market is experiencing a CAGR of 7.9% during (2020 - 2026).
The Hospitals market dominated the Saudi Arabia Liver Disease Diagnostics Market by End User in 2019, growing at a CAGR of 7.5 % during the forecast period. The Laboratories market is expected to witness a CAGR of 8.3% during (2020 - 2026).
The Imaging market dominated the South Africa Liver Disease Diagnostics Market by Diagnosis Technique in 2019, growing at a CAGR of 7.8 % during the forecast period. The Biopsy market is poised to witness a CAGR of 8.2% during (2020 - 2026). Additionally, The Endoscopy market is estimated to grow at highest CAGR of 8.6% during (2020 - 2026).
Structural Insights: https://www.kbvresearch.com/lamea-liver-disease-diagnostics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Abbott Laboratories, F. Hoffmann-La Roche Ltd., Boston Scientific Corporation, Siemens AG (Siemens Healthineers), Bayer AG, Merck & Co., Inc., Sanofi S.A., Novartis AG, Pfizer, Inc., and Randox laboratories limited.
By Diagnosis Technique
Unique Offerings from KBV Research